CRISPR Therapeutics AG is part of the biotechnology industry and healthcare sector. The company CEO is Samarth Kulkarni. CRISPR Therapeutics AG is a gene editing company. It is engaged in the development of CRISPR/Cas9-based therapeutics.

Previous Intraday Performance:

The CRSP shares had a previous change of -3.93% which opened at 35.40 and closed at 34.19. It moved to an intraday high of 35.91 and a low of 33.55.

SeekingAlpha:  CRISPR Therapeutics (CRSP) Investor Presentation – Slideshow

Historical Performance:

Over the last five trading days, CRSP shares returned -8.19% and in the past 30 trading days it returned 9.83%. Over three months, it changed 29.95%. In one year it has changed -34.59% and within that year its 52-week high was 73.90 and its 52-week low was 22.22. CRSP stock is 53.87% above its 52 Week Low.

Our calculations result in a 200 day moving average of 42.94 and a 50 day moving average of 34.83. Right now, CRSP stock is trading -20.39% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.

SeekingAlpha:  Key events next week – healthcare


The company has a market cap of $1.8b with 52.3m shares outstanding and a float of 50.5m shares. Trading volume was 760,429 shares and has experienced an average volume of 837,701 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is good.


The last annual reported EPS for CRISPR Therapeutics AG was -3.43 which ended on 31st of December 2018. Based on 3 analyst estimates, the consensus EPS for the next quarter is -0.78.

Below was the last reported quarterly earnings per share:
12-31-2018:  -0.92
09-30-2018:  -1.07
06-30-2018:  -0.82
03-31-2018:  -0.62

The next earnings report will be: 03-28-2019

EPS growth is an important number as it indicates the future prospects of CRISPR Therapeutics AG; the EPS growth rate, as it is usually called, is typically displayed as a percentage, which at this time is hard to estimate, but revenue growth has been -93.60% over the last twelve months.

Indicators Also to Watch:

Based on the latest filings, there is 3.90% of insider ownership and 54.40% of institutional ownership.

I calculated the beta to be 3.12

SeekingAlpha:  Key events next week – healthcare

Fundamental Numbers:

Based on last reported financials, the company’s return on equity is -56.89%, return on assets is -43.40%, price-to-sales is 595.59 and price-to-book is 4.74.

Company Score Card:

Results are out of six:
 2  : Growth Expectations Result
 6  : Financial Safety Result
 0  : Past Performance Result
 0  : Valuation Result
 0  : Dividend Safety Result
 2  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).


Please enter your comment!
Please enter your name here